Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11

BACKGROUND: Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability of dulaglutide at once-weekly doses of 1.5, 3.0,...

Descripción completa

Detalles Bibliográficos
Autores principales: Van, Joanna, Frias, Juan P., Bonora, Enzo, Raha, Sohini, Meyer, Jarrett, Jung, Heike, Cox, David, Konig, Manige, Peleshok, Jennifer, Bethel, M. Angelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479017/
https://www.ncbi.nlm.nih.gov/pubmed/34514554
http://dx.doi.org/10.1007/s13300-021-01140-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479017/
https://www.ncbi.nlm.nih.gov/pubmed/34514554
http://dx.doi.org/10.1007/s13300-021-01140-9

Ejemplares similares